Gilead Sciences Acquires CymaBay Therapeutics in $4.3 Billion Deal to Expand Liver Disease Portfolio
In a major move to enhance its array of liver disease treatments, Gilead Sciences has announced its acquisition of CymaBay Therapeutics for a staggering $4.3 billion. The deal, set to conclude in the first quarter of 2024, will see Gilead pay $32.50 per share in cash for the company.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
